O'Ryan Miguel, Vidal Roberto, del Canto Felipe, Salazar Juan Carlos, Montero David
a Microbiology and Mycology Program; Institute of Biomedical Sciences; Universidad de Chile ; Santiago , Chile.
Hum Vaccin Immunother. 2015;11(3):584-600. doi: 10.1080/21645515.2015.1011019.
Efforts to develop vaccines for prevention of acute diarrhea have been going on for more than 40 y with partial success. The myriad of pathogens, more than 20, that have been identified as a cause of acute diarrhea throughout the years pose a significant challenge for selecting and further developing the most relevant vaccine candidates. Based on pathogen distribution as identified in epidemiological studies performed mostly in low-resource countries, rotavirus, Cryptosporidium, Shigella, diarrheogenic E. coli and V. cholerae are predominant, and thus the main targets for vaccine development and implementation. Vaccination against norovirus is most relevant in middle/high-income countries and possibly in resource-deprived countries, pending a more precise characterization of disease impact. Only a few licensed vaccines are currently available, of which rotavirus vaccines have been the most outstanding in demonstrating a significant impact in a short time period. This is a comprehensive review, divided into 2 articles, of nearly 50 vaccine candidates against the most relevant viral and bacterial pathogens that cause acute gastroenteritis. In order to facilitate reading, sections for each pathogen are organized as follows: i) a discussion of the main epidemiological and pathogenic features; and ii) a discussion of vaccines based on their stage of development, moving from current licensed vaccines to vaccines in advanced stage of development (in phase IIb or III trials) to vaccines in early stages of clinical development (in phase I/II) or preclinical development in animal models. In this first article we discuss rotavirus, norovirus and Vibrio cholerae. In the following article we will discuss Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic), and Campylobacter jejuni.
开发预防急性腹泻疫苗的努力已经持续了40多年,取得了部分成功。多年来已被确定为急性腹泻病因的病原体众多,超过20种,这对选择和进一步开发最相关的候选疫苗构成了重大挑战。根据主要在资源匮乏国家进行的流行病学研究确定的病原体分布情况,轮状病毒、隐孢子虫、志贺氏菌、致泻性大肠杆菌和霍乱弧菌占主导地位,因此是疫苗开发和实施的主要目标。在中高收入国家以及可能在资源匮乏国家,针对诺如病毒的疫苗接种最为相关,但前提是要更精确地确定疾病影响。目前仅有少数几种获得许可的疫苗,其中轮状病毒疫苗在短时间内产生显著影响方面最为突出。这是一篇分为两篇文章的综述,涵盖了近50种针对引起急性肠胃炎的最相关病毒和细菌病原体的候选疫苗。为便于阅读,针对每种病原体的章节安排如下:i)主要流行病学和致病特征的讨论;ii)基于疫苗研发阶段的讨论,从当前已获许可的疫苗到处于研发后期(IIb期或III期试验)的疫苗,再到处于临床研发早期(I/II期)或动物模型临床前研发阶段的疫苗。在第一篇文章中,我们讨论轮状病毒、诺如病毒和霍乱弧菌。在后续文章中,我们将讨论志贺氏菌、沙门氏菌(非伤寒型)、致泻性大肠杆菌(产肠毒素型和肠出血型)以及空肠弯曲菌。